Clinical Trial Update: Study of Safety and Tolerability of Multiple Intravenous Doses of ANZ-521 in Adults With Chronic Hepatitis C Virus [Phase 1, Phase 2]

View source ↗

Summary

This clinical trial update reports termination of a Phase 1/2 study assessing safety and tolerability of multiple intravenous doses of ANZ-521 in adults with Ch…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatitis C

Drugs mentioned

• ANZ-521

Snippet

Sponsor: Anza Therapeutics, Inc. | Conditions: Chronic Hepatitis C | Phase 1, Phase 2 | Status: TERMINATED